对于升高高密度脂蛋白药物胆固醇酯转运蛋白抑制剂的研究进展及其机制的探讨

Advances in research on the inhibitors of high density lipoprotein cholesteryl ester transfer protein and its mechanism

高密度脂蛋白(HDL)通过其特有的胆固醇逆转运功能起到了抗动脉粥样硬化及冠心病的作用。大量临床及流行病研究已证实高密度脂蛋白胆固醇(HDL-C)的含量水平与心血管风险呈负相关,因此如何提高HDL-C水平已成为了各方关注的焦点,但升高HDL-C药物的研发却屡屡受挫。进一步探讨HDL的结构,功能有助于分析升高HDL-C药物失败的可能原因及机制,对于临床和基础研究有着重要的意义。

High-density lipoprotein（ HDL） plays a role in anti-atherosclerosis and anti-coronary heart disease through its unique function that reverse cholesterol transport. A large number of clinical and epidemiology studies have proved that high density lipoprotein cholesterol（ HDL-C） levels were negatively correlated with cardiovascular risk,so how to improve the level of HDL-C has become the focus of attention,but the development of raising HDL-C drugs failed repeatedly. Further discussion on the structure and function of HDL will help to analyze the possible causes and mechanisms of the failure of raising HDL-C drugs,which is of great significance for clinical and basic research.